Immunoprecise Antibodies Ltd (CVE:IPA, OTC PINK:IPATF) has appointed Robert Burke as a director to help the firm assess the scientific efficacy of its strategic acquisitions globally.
Dr Burke fills the vacancy left by Thomas D'Orazio, who has left as director, and brings significant scientific depth and experience in the production and characterization of antibodies, the firm said.
He is an emeritus professor at the University of Victoria, where he was a faculty member for over 35 years.
He has published over 100 peer-reviewed publications and has supervised numerous trainees.
"With the appointment of Dr. Robert Burke to the board of directors, IPA continues its history of bringing leading scientific capability to assist the company to become a leading integrated antibody solutions company with global reach," said Dr James Kuo, chairman and interim president of the company.
Immunoprecise Antibodies Ltd shares added 1.92% in Toronto to C$0.53.